¼¼°èÀÇ ¼¾Æ®·² ·¦ ½ÃÀå
Central Labs
»óǰÄÚµå : 1779751
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 290 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¼¾Æ®·² ·¦ ½ÃÀåÀº 2030³â±îÁö 46¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 34¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¼¾Æ®·² ·¦ ½ÃÀåÀº 2024-2030³â¿¡ CAGR 5.3%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 46¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ À¯ÀüÀÚ ¼­ºñ½º´Â CAGR 6.2%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 14¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿ ¼­ºñ½º ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 5.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 9¾ï 2,400¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼¾Æ®·² ·¦ ½ÃÀåÀº 2024³â¿¡´Â 9¾ï 2,400¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 9¾ï 3,100¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 8.5%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.5%¿Í 5.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¼¾Æ®·² ·¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Áß¾Ó¿¬±¸¼Ò¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Áß¾Ó¿¬±¸¼Ò´Â ÀÓ»ó½ÃÇè¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖÀ¸¸ç, ÀǾàǰ °³¹ß ¹× ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀο¡ ÇʼöÀûÀΠǥÁØÈ­µÈ °íǰÁú °Ë»ç ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ƯÈ÷ Á¾¾çÇÐ, ½Å°æÇÐ, °¨¿°ÇÐ ºÐ¾ßÀÇ ÀÓ»ó½ÃÇèÀÌ Áõ°¡Çϸ鼭 Áß¾Ó°Ë»ç½Ç ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷Àº Áø´Ü °Ë»ç ¹× ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®ÀÇ Àϰü¼º, ±ÔÁ¤ Áؼö ¹× È¿À²¼ºÀ» º¸ÀåÇϱâ À§ÇØ ½ÇÇè½Ç ±â´ÉÀ» Áß¾Ó ½ÇÇè½Ç¿¡ ¾Æ¿ô¼Ò½ÌÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÓ»ó½ÃÇèÀÇ º¹À⼺ÀÌ Áõ°¡Çϸ鼭 ¾àµ¿ÇÐ, À¯ÀüüÇÐ, µ¿¹ÝÁø´Ü µî Àü¹®ÀûÀÎ °Ë»ç ¼­ºñ½º°¡ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ´Ù±â°ü ½ÃÇè¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ½Å·Ú¼º°ú È®À强ÀÌ ³ôÀº °Ë»ç ¼­ºñ½º¿¡ ´ëÇÑ ¿ä±¸´Â ½ºÆù¼­ ¹× ÀǾàǰ °³¹ß ¼öʱâ°ü(CRO)À» Áß¾Ó¿¬±¸¼Ò¿ÍÀÇ Á¦ÈÞ·Î À¯µµÇϰí ÀÖ½À´Ï´Ù. ¼¼°è Àӻ󿬱¸ÀÇ Àü¸ÁÀÌ È®´ëµÊ¿¡ µû¶ó Á¤¹ÐÀÇ·á ±¸»óÀ» Áö¿øÇÏ´Â Áß¾Ó¿¬±¸¼ÒÀÇ ¿ªÇÒÀÌ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº Áß¾Ó ¿¬±¸¼Ò¸¦ ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

½ÇÇè½Ç ÀÚµ¿È­, ÀΰøÁö´É(AI), µðÁöÅÐ º´¸®ÇÐ(Digital Pathology)ÀÇ Çõ½ÅÀº Áß¾Ó ½ÇÇè½Ç ¿î¿µ¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÷´Ü ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ Áú·®ºÐ¼®(LC-MS), Â÷¼¼´ë ½ÃÄö½Ì(NGS), ÇÏÀ̽º·çDz ½ºÅ©¸®´× ±â¼úÀ» ÅëÇØ ÀÓ»ó ½Ã·á¸¦ º¸´Ù Á¤È®ÇÏ°í ºü¸£°Ô ºÐ¼®ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úµéÀº °Ë»ç Á¤È®µµ¸¦ Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó, ÀÓ»ó½ÃÇè¿¡¼­ µ¥ÀÌÅÍÀÇ ¹«°á¼º°ú ÀçÇö¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ½ÇÇè½Ç Á¤º¸ °ü¸® ½Ã½ºÅÛ(LIMS)ÀÇ µµÀÔµµ ÁÖ¿ä ¹ßÀü Áß Çϳª·Î, ¿©·¯ ÀÓ»ó½ÃÇè ±â°ü¿¡¼­ ½Ç½Ã°£À¸·Î µ¥ÀÌÅ͸¦ °øÀ¯Çϰí ÅëÇÕÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ µ¥ÀÌÅÍ ºÐ¼®µµ ÀÓ»ó µ¥ÀÌÅÍÀÇ ÆÐÅÏÀ» ÆÄ¾ÇÇϰí ÀÓ»ó½ÃÇè ÇÁ·ÎÅäÄÝÀ» ÃÖÀûÈ­ÇÏ¿© ÀÓ»ó½ÃÇèÀÇ È¿À²¼ºÀ» ³ôÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã°¡ °­È­µÇ°í °íǰÁú ÀÓ»ó½ÃÇè µ¥ÀÌÅͰ¡ ¿ä±¸µÇ´Â °¡¿îµ¥, Áß¾Ó¿¬±¸¼Ò´Â ±â¼úÀ» Ȱ¿ëÇÏ¿© ÄÄÇöóÀ̾ð½º, È¿À²¼º, ½ÃÇè °á°úÀÇ ½Å·Ú¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

Áß¾Ó¿¬±¸¼ÒÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ½ÃÀå µ¿ÇâÀº?

Áß¾Ó¿¬±¸¼Ò ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Å« È帧 Áß Çϳª´Â ¹ÙÀÌ¿À¸¶Ä¿ Áß½ÉÀÇ ÀǾàǰ °³¹ßÀÌ °­Á¶µÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. Á¤¹ÐÀÇÇÐ Á¢±Ù¹ý¿¡´Â Áúº´ ƯÀÌÀû ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°Çϱâ À§ÇÑ Ã·´Ü ½ÇÇè½Ç °Ë»ç°¡ ÇÊ¿äÇϸç, ÀÌ´Â Á¦¾àȸ»ç¿Í Áß¾Ó¿¬±¸¼ÒÀÇ Çù·Â °ü°è¸¦ °­È­ÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºÐ»êÇü ÀÓ»ó½ÃÇè°ú °¡»ó ÀÓ»ó½ÃÇèÀÇ ºÎ»óµµ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, Áß¾Ó ½ÇÇè½ÇÀº ¿ø°Ý »ùÇà ¼öÁý ¹× ½Ç½Ã°£ Áø´Ü ¼­ºñ½º Á¦°ø¿¡ ÀûÀÀÇϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ µ¿ÇâÀº ½ÅÈï ½ÃÀå¿¡¼­ÀÇ Áß¾Ó ¿¬±¸¼Ò ³×Æ®¿öÅ©ÀÇ È®´ëÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× ¶óƾ¾Æ¸Þ¸®Ä« µîÀÇ Áö¿ª¿¡¼­ ÀÓ»ó½ÃÇè Ȱµ¿ÀÌ È°¹ßÇØÁü¿¡ µû¶ó ÁÖ¿ä Áß¾Ó ¿¬±¸¼Ò´Â ÇØ´ç Áö¿ª¿¡ ½Ã¼³À» ¼³¸³ÇÏ°í ±¹Á¦ °øµ¿ ÀÓ»ó½ÃÇèÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦ ´ç±¹ÀÌ ÀÓ»ó½ÃÇè ¼öÇà ±âÁØ(GCLP)¿¡ ´ëÇÑ Á߿伺À» °­Á¶ÇÔ¿¡ µû¶ó Áß¾Ó¿¬±¸¼Ò´Â ǰÁú º¸Áõ ÇÁ·Î±×·¥ ¹× ÀÎÁõ ±¸»ó¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÇâÈÄ ¼ö³â°£ Áß¾Ó °Ë»ç½Ç ¼­ºñ½ºÀÇ ÁøÈ­¸¦ ´õ¿í ±¸Ã¼È­ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Áß¾Ó ½ÇÇè½Ç ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

Áß¾Ó ½ÇÇè½Ç ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»ó½ÃÇèÀÇ º¹À⼺ Áõ°¡, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¹ÙÀÌ¿À¸¶Ä¿ Áß½ÉÀÇ ¿¬±¸·® Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀǾàǰ ¿¬±¸°³¹ßÀÇ ¾Æ¿ô¼Ò½Ì µ¿Çâµµ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ±â¾÷Àº ÀǾàǰ °³¹ß ÀÏÁ¤À» ¾Õ´ç±â°í ¿î¿µ ºñ¿ëÀ» Àý°¨Çϱâ À§ÇØ Àü¹® ¿¬±¸¼ÒÀÇ Àü¹®¼ºÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Èñ±ÍÁúȯ ¹× »ý¹°Á¦Á¦¸¦ Áß½ÉÀ¸·Î ÇÑ ¼¼°è ÀÓ»ó½ÃÇè Ȱµ¿ÀÇ È®´ë´Â Àü¹®È­µÈ Áß¾Ó ½ÇÇè½Ç ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ ½ÇÇè½Ç Å×½ºÆ® ÇÁ·ÎÅäÄÝÀ» ¿ä±¸ÇÏ´Â ±ÔÁ¦ ¿ä°ÇÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ¹× »ý¸í°úÇÐ »ê¾÷ÀÌ µðÁöÅÐ Àüȯ°ú AI ±â¹Ý ºÐ¼®À» Áö¼ÓÀûÀ¸·Î µµÀÔÇϰí ÀÖ´Â °¡¿îµ¥, ¼¾Æ®·²·¦Àº ÀÓ»ó½ÃÇè ¹× ÀǾàǰ °³¹ß ÇÁ·Î±×·¥ÀÇ ¼º°øÀ» º¸ÀåÇÏ´Â µ¥ ÇʼöÀûÀÎ ÆÄÆ®³Ê·Î ÀÚ¸®¸Å±èÇÒ °ÍÀÔ´Ï´Ù.

ºÎ¹®

¼­ºñ½º À¯Çü(À¯ÀüÀÚ ¼­ºñ½º, ¹ÙÀÌ¿À¸¶Ä¿ ¼­ºñ½º, ¹Ì»ý¹°ÇÐ ¼­ºñ½º, ÇØºÎ º´¸®ÇÐ/Á¶Á÷ÇÐ, °Ëü °ü¸®¡¤º¸°ü, Ư¼öÈ­ÇÐ ¼­ºñ½º, ±âŸ ¼­ºñ½º), ÃÖÁ¾»ç¿ëÀÚ(Á¦¾àȸ»ç, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, Çмú¡¤¿¬±¸±â°ü)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Central Labs Market to Reach US$4.6 Billion by 2030

The global market for Central Labs estimated at US$3.4 Billion in the year 2024, is expected to reach US$4.6 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Genetic Services, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Biomarker Services segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$924.0 Million While China is Forecast to Grow at 8.5% CAGR

The Central Labs market in the U.S. is estimated at US$924.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$931.0 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Central Labs Market - Key Trends & Drivers Summarized

Why Is the Demand for Central Labs Increasing?

Central laboratories play a critical role in clinical trials, providing standardized and high-quality testing services essential for drug development and regulatory approvals. The increasing number of clinical trials, particularly in oncology, neurology, and infectious diseases, is driving the demand for central lab services. Pharmaceutical and biotechnology companies are outsourcing laboratory functions to central labs to ensure consistency, compliance, and efficiency in diagnostic testing and biomarker analysis. Additionally, the complexity of clinical trials has increased, requiring specialized testing services such as pharmacokinetics, genomics, and companion diagnostics. The need for reliable and scalable laboratory services that can handle multi-site trials is pushing sponsors and contract research organizations (CROs) toward central lab partnerships. As the global clinical research landscape expands, the role of central labs in supporting precision medicine initiatives is becoming increasingly significant.

How Are Technological Advancements Transforming Central Labs?

Technological innovations in laboratory automation, artificial intelligence (AI), and digital pathology are revolutionizing central lab operations. Advanced liquid chromatography-mass spectrometry (LC-MS), next-generation sequencing (NGS), and high-throughput screening techniques are enabling more precise and rapid analysis of clinical samples. These technologies are not only improving test accuracy but also enhancing data integrity and reproducibility in clinical trials. The adoption of cloud-based laboratory information management systems (LIMS) is another key development, allowing real-time data sharing and integration across multiple trial sites. AI-driven data analytics are also playing a crucial role in improving trial efficiency by identifying patterns in clinical data and optimizing trial protocols. With increasing regulatory scrutiny and the demand for high-quality clinical trial data, central labs are leveraging technology to enhance compliance, efficiency, and reliability in test results.

What Market Trends Are Driving the Growth of Central Labs?

One of the major trends influencing the central labs market is the growing emphasis on biomarker-driven drug development. Precision medicine approaches require sophisticated laboratory testing to identify disease-specific biomarkers, leading to increased collaboration between pharmaceutical companies and central labs. The rise of decentralized and virtual clinical trials is also impacting the market, with central labs adapting to provide remote sample collection and real-time diagnostic services. Another notable trend is the expansion of central lab networks in emerging markets. As clinical trial activity grows in regions such as Asia-Pacific and Latin America, leading central labs are establishing facilities in these locations to support global trials. Additionally, regulatory authorities are placing greater emphasis on Good Clinical Laboratory Practices (GCLP), driving central labs to invest in quality assurance programs and accreditation initiatives. These trends are expected to further shape the evolution of central lab services in the coming years.

What Are the Key Growth Drivers in the Central Labs Market?

The growth in the Central Labs market is driven by several factors, including the increasing complexity of clinical trials, the growing demand for precision medicine, and the rising volume of biomarker-driven research. The outsourcing trend in pharmaceutical R&D is also playing a pivotal role, as companies seek specialized laboratory expertise to accelerate drug development timelines and reduce operational costs. Additionally, the expansion of global clinical trial activity, particularly in rare diseases and biologics, is fueling demand for specialized central lab services. Regulatory requirements mandating rigorous laboratory testing protocols are further reinforcing the market’s growth. As the healthcare and life sciences industries continue to embrace digital transformation and AI-powered analytics, central labs will remain essential partners in ensuring the success of clinical trials and drug development programs.

SCOPE OF STUDY:

The report analyzes the Central Labs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service Type (Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology/Histology, Specimen Management and Storage, Special Chemistry Services, Other Services); End-Use (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â